Alexion Pharmaceuticals Liabilities 2024

Alexion Pharmaceuticals Aktienanalyse

What does Alexion Pharmaceuticals do?

Alexion Pharmaceuticals Inc. is a US biotechnology company specializing in the development and commercialization of drugs for the treatment of rare diseases. It was founded in 1992 and is headquartered in Boston, Massachusetts. The history of Alexion began with the discovery of the protein C5a, which is responsible for the occurrence of inflammation. Alexion then developed the first medication, Soliris, specifically for the treatment of the rare genetic disease paroxysmal nocturnal hemoglobinuria (PNH). Soliris is classified as a monoclonal antibody and inhibits the protein C5a, which is responsible for inflammation. Alexion's business model focuses primarily on developing drugs for rare diseases. These diseases are unprofitable for most major pharmaceutical companies because they have a small patient base. However, Alexion has begun to identify and develop drugs for such diseases that are tailored to these specific patients. Such drugs are not suitable for the majority of the patient population as they are very expensive. Alexion is divided into several divisions focused on the development and launch of drugs for specific diseases. The most well-known division is PNH, but the company has also developed drugs for rare hematological, nephrological, neurological, immunological, and metabolic diseases. Alexion has also developed the ability to bring drugs to market faster than other pharmaceutical companies by employing innovative clinical trial methods. In addition to Soliris, Alexion has developed other drugs such as Ultomiris, Strensiq, and Kanuma. Ultomiris is a successor to Soliris and is used to treat PNH and aHUS. Strensiq is used for patients with hypophosphatasia, while Kanuma was developed for patients with lysosomal storage diseases such as children with Gaucher disease or Fabry disease. Alexion also collaborates with other companies to develop and market drugs for rare diseases. The most well-known example is the collaboration with the Japanese pharmaceutical company Mitsubishi Tanabe Pharma Corporation to develop the drug ALXN1210, which Alexion hopes will surpass both Soliris and Ultomiris. The collaboration has the potential to provide groundbreaking treatment for PNH, aHUS, and other rare diseases. Overall, in recent years, Alexion Pharmaceuticals Inc. has become an important player in the market for rare diseases. The company has taken on challenging tasks by striving to uncover rare diseases and gaps and then finding new, unique solutions to treat these diseases. In the future, Alexion will continue its efforts in researching and developing drugs for rare diseases and will continue to provide innovative solutions and therapeutic approaches to improve the lives of patients. Alexion Pharmaceuticals ist eines der beliebtesten Unternehmen auf Eulerpool.com.

Alexion Pharmaceuticals revenue by segment

100 % Therapies

Liabilities Details

Assessing Alexion Pharmaceuticals's Liabilities

Alexion Pharmaceuticals's liabilities constitute the company's financial obligations and debts owed to external parties and stakeholders. They are categorized into current liabilities, due within a year, and long-term liabilities, which are due over a longer period. A detailed assessment of these liabilities is crucial for evaluating Alexion Pharmaceuticals's financial stability, operational efficiency, and long-term viability.

Year-to-Year Comparison

By comparing Alexion Pharmaceuticals's liabilities year-over-year, investors can identify trends, shifts, and anomalies in the company’s financial positioning. A decrease in total liabilities often signals financial strengthening, while an increase might indicate enhanced investments, acquisitions, or potential financial strain.

Impact on Investments

Alexion Pharmaceuticals's total liabilities play a significant role in determining the company's leverage and risk profile. Investors and analysts examine this aspect meticulously to ascertain the firm’s ability to meet its financial obligations, which influences investment attractiveness and credit ratings.

Interpreting Liability Fluctuations

Shifts in Alexion Pharmaceuticals’s liability structure indicate changes in its financial management and strategy. A reduction in liabilities reflects efficient financial management or debt payoffs, while an increase may suggest expansion, acquisition activities, or accruing operational expenses, each carrying distinct implications for investors.

Frequently Asked Questions about Alexion Pharmaceuticals stock

What is the level of liabilities of Alexion Pharmaceuticals this year?

Alexion Pharmaceuticals has a debt balance of 0 USD this year.

What were the liabilities of Alexion Pharmaceuticals compared to the previous year?

The liabilities of Alexion Pharmaceuticals have increased by 0% dropped compared to the previous year.

What are the consequences of high debt for investors of Alexion Pharmaceuticals?

High liabilities can pose a risk for investors of Alexion Pharmaceuticals, as they can weaken the company's financial position and impair its ability to meet its obligations.

What consequences do low liabilities have for investors in Alexion Pharmaceuticals?

Low liabilities mean that Alexion Pharmaceuticals has a strong financial position and is able to meet its obligations without overburdening its finances.

How does an increase in liabilities of Alexion Pharmaceuticals affect the company?

An increase in liabilities of Alexion Pharmaceuticals can lead to the company having more obligations and potentially find it more difficult to meet its financial commitments.

How does a reduction in the liabilities of Alexion Pharmaceuticals affect the company?

A decrease in the liabilities of Alexion Pharmaceuticals can lead to the company having fewer obligations and a stronger financial position, which can make it easier for the company to fulfill its financial commitments.

What are some factors that influence the liabilities of Alexion Pharmaceuticals?

Some factors that can influence the liabilities of Alexion Pharmaceuticals include investments, acquisitions, operating costs, and sales development.

Why is the level of liabilities of Alexion Pharmaceuticals so important for investors?

The liabilities of Alexion Pharmaceuticals are important for investors as they serve as an indicator of the company's financial stability and provide investors with information on how the company meets its financial obligations.

What strategic measures can Alexion Pharmaceuticals take to modify the liabilities?

To change its liabilities, Alexion Pharmaceuticals can take measures such as cost savings, increasing revenue, selling assets, raising investments, or forming partnerships. It is important for the company to conduct a thorough review of its financial situation to choose the best strategic actions.

How much dividend does Alexion Pharmaceuticals pay?

Over the past 12 months, Alexion Pharmaceuticals paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Alexion Pharmaceuticals is expected to pay a dividend of 0 USD.

What is the dividend yield of Alexion Pharmaceuticals?

The current dividend yield of Alexion Pharmaceuticals is .

When does Alexion Pharmaceuticals pay dividends?

Alexion Pharmaceuticals pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Alexion Pharmaceuticals?

Alexion Pharmaceuticals paid dividends every year for the past 0 years.

What is the dividend of Alexion Pharmaceuticals?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Alexion Pharmaceuticals located?

Alexion Pharmaceuticals is assigned to the 'Health' sector.

Wann musste ich die Aktien von Alexion Pharmaceuticals kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Alexion Pharmaceuticals from 11/19/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 11/19/2024.

When did Alexion Pharmaceuticals pay the last dividend?

The last dividend was paid out on 11/19/2024.

What was the dividend of Alexion Pharmaceuticals in the year 2023?

In the year 2023, Alexion Pharmaceuticals distributed 0 USD as dividends.

In which currency does Alexion Pharmaceuticals pay out the dividend?

The dividends of Alexion Pharmaceuticals are distributed in USD.